Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance

- Ended third quarter with $24.1 million in cash and restricted cash - Expects positive fourth quarter earnings between $0.01 and $0.04 per share

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.